Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)*
ALBIREO PHARMA, INC.
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
01345P 106
(CUSIP Number)
Charles Sermon
Phase4 Partners Limited
1 Cavendish Place
London W1G 0QF, United Kingdom
Telephone: +44 0 20 3036 0050
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
February 27, 2019
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note. Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
| * |
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this
form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
CUSIP No. 01345P 106
|
Schedule 13D
|
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
|
Phase4 Partners Limited
|
|
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
|
(b)
|
☒ (joint filers)
|
||||
|
|
|
||||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
SOURCE OF FUNDS
|
|
|
||
|
OO
|
|
|
|||
|
|
|
||||
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
England and Wales
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
|
0 shares1
|
|
|
|||
|
|
|
||||
|
8
|
SHARED VOTING POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
0 shares1
|
|
|
|||
|
|
|
||||
|
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
0 shares1
|
|
|
|||
|
|
|
||||
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
|
0%2
|
|
|
|||
|
|
|
||||
|
14
|
TYPE OF REPORTING PERSON
|
|
|
||
| OO |
|
|
|||
|
|
|
||||
| 1 |
Represents shares held by Phase4 Ventures III GP LP (“Phase4 GPLP”) in its capacity as general partner of Phase4 Ventures III LP (“Phase4 III”). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase4 Ventures III General Partner Limited (“Phase4
GP”). Phase4 GP has appointed Phase4 Partners Limited (“Phase4 Partners”) to act as the manager of Phase4 III. Phase4 Partners ultimately exercises voting and investment power over the securities held by Phase4 GPLP. Dr. Alastair McKinnon, Denise
Scots-Knight, Ph.D. and Charles Sermon are Directors of Phase4 Partners. Phase4 Partners, Phase4 GP, Phase4 GPLP and Phase4 III may each be deemed to have sole voting and dispositive power over the shares and Dr. McKinnon, Dr.
Scots-Knight and Mr. Sermon may each be deemed to have shared voting and dispositive power over the shares.
|
| 2 |
The percentage ownership was calculated based on 11,897,146 shares of common stock outstanding as of the March 1, 2018, as disclosed in the Annual Report on Form 10-K for
the fiscal year ended December 31, 2018 filed by Albireo Pharma, Inc. (the “Issuer”) with the Securities and Exchange Commission on March 27, 2018.
|
|
CUSIP No. 01345P 106
|
Schedule 13D
|
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
|
Phase4 Ventures III LP
|
|
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
|
(b)
|
☒ (joint filers)
|
||||
|
|
|
||||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
SOURCE OF FUNDS
|
|
|
||
|
OO
|
|
|
|||
|
|
|
||||
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
England and Wales
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
|
0 shares3
|
|
|
|||
|
|
|
||||
|
8
|
SHARED VOTING POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
0 shares3
|
|
|
|||
|
|
|
||||
|
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
0 shares3
|
|
|
|||
|
|
|
||||
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
|
0%4
|
|
|
|||
|
|
|
||||
|
14
|
TYPE OF REPORTING PERSON
|
|
|
||
|
PN
|
|
|
|||
|
|
|
||||
| 3 |
See footnote 1.
|
| 4 |
See footnote 2.
|
|
CUSIP No. 01345P 106
|
Schedule 13D
|
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
|
Phase4 Ventures III GP LP
|
|
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
|
(b)
|
☒ (joint filers)
|
||||
|
|
|
||||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
SOURCE OF FUNDS
|
|
|
||
|
OO
|
|
||||
|
|
|
||||
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
Scotland
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
|
0 shares5
|
|
|
|||
|
|
|
||||
|
8
|
SHARED VOTING POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
0 shares5
|
|
|
|||
|
|
|
||||
|
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
0 shares5
|
|
|
|||
|
|
|
||||
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
|
0%6
|
|
|
|||
|
|
|
||||
|
14
|
TYPE OF REPORTING PERSON
|
|
|
||
|
PN
|
|
|
|||
|
|
|
||||
| 5 |
See footnote 1.
|
| 6 |
See footnote 2.
|
|
CUSIP No. 01345P 106
|
Schedule 13D
|
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
|
Phase4 Ventures III General Partner Limited
|
|
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
|
(b)
|
☒ (joint filers)
|
||||
|
|
|
||||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
SOURCE OF FUNDS
|
|
|
||
|
OO
|
|
|
|||
|
|
|
||||
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
Scotland
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
|
0 shares7
|
|
|
|||
|
|
|
||||
|
8
|
SHARED VOTING POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
0 shares7
|
|
|
|||
|
|
|
||||
|
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
0 shares7
|
|
|
|||
|
|
|
||||
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
|
0%8
|
|
|
|||
|
|
|
||||
|
14
|
TYPE OF REPORTING PERSON
|
|
|
||
|
OO
|
|
|
|||
|
|
|
||||
| 7 |
See footnote 1.
|
| 8 |
See footnote 2.
|
|
CUSIP No. 01345P 106
|
Schedule 13D
|
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
|
Dr. Alastair McKinnon
|
|
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
|
(b)
|
☒ (joint filers)
|
||||
|
|
|
||||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
SOURCE OF FUNDS
|
|
|
||
|
OO
|
|
|
|||
|
|
|
||||
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
United Kingdom
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
| 0 shares |
|
|
|||
|
|
|
||||
|
8
|
SHARED VOTING POWER
|
|
|
||
|
0 shares9
|
|
|
|||
|
|
|
||||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0 shares9
|
|
|
|||
|
|
|
||||
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
0 shares9
|
|
|
|||
|
|
|
||||
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
|
0%10
|
|
|
|||
|
|
|
||||
|
14
|
TYPE OF REPORTING PERSON
|
|
|
||
|
IN
|
|
|
|||
|
|
| ||||
| 9 |
See footnote 1.
|
| 10 |
See footnote 2.
|
|
CUSIP No. 01345P 106
|
Schedule 13D
|
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
|
Denise Scots-Knight, Ph.D.
|
|
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
|
(b)
|
☒ (joint filers)
|
||||
|
|
|
||||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
SOURCE OF FUNDS
|
|
|
||
|
OO
|
|
|
|||
|
|
|
||||
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
United Kingdom
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
|
0 shares
|
|
|
|||
|
|
|
||||
|
8
|
SHARED VOTING POWER
|
|
|
||
|
0 shares11
|
|
|
|||
|
|
|
||||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0 shares11
|
|
|
|||
|
|
|
||||
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
0 shares11
|
|
|
|||
|
|
|
||||
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
| 0%12 |
|
|
|||
|
|
|
||||
|
14
|
TYPE OF REPORTING PERSON
|
|
|
||
|
IN
|
|
|
|||
|
|
|
||||
| 11 |
See footnote 1.
|
| 12 |
See footnote 2.
|
|
CUSIP No. 01345P 106
|
Schedule 13D
|
|
1
|
NAME OF REPORTING PERSON
|
|
|
||
|
Charles Sermon
|
|
|
|||
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
(a)
|
☐
|
||
|
(b)
|
☒ (joint filers)
|
||||
|
|
|
||||
|
3
|
SEC USE ONLY
|
|
|
||
|
|
|
|
|||
|
|
|
||||
|
4
|
SOURCE OF FUNDS
|
|
|
||
|
OO
|
|
|
|||
|
|
|
||||
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
|
|
|
||
|
United Kingdom
|
|
|
|||
|
|
|
||||
|
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
7
|
SOLE VOTING POWER
|
|
|
|
|
0 shares
|
|
|
|||
|
|
|
||||
|
8
|
SHARED VOTING POWER
|
|
|
||
|
0 shares13
|
|
|
|||
|
|
|
||||
|
9
|
SOLE DISPOSITIVE POWER
|
|
|
||
|
0 shares
|
|
|
|||
|
|
|
||||
|
10
|
SHARED DISPOSITIVE POWER
|
|
|
||
|
0 shares13
|
|
|
|||
|
|
|
||||
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
|
|
|
||
|
0 shares13
|
|
|
|||
|
|
|
||||
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
|
|
☐
|
||
|
|
|
||||
|
|
|
||||
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
|
|
|
||
|
%14
|
|
|
|||
|
|
|
||||
|
14
|
TYPE OF REPORTING PERSON
|
|
|
||
|
IN
|
|
|
|||
|
|
|
||||
| 13 |
See footnote 1.
|
| 14 |
See footnote 2.
|
Schedule 13D
This Amendment No. 2 (“Amendment No. 2”) amends the Statement on Schedule
13D first filed with the Securities and Exchange Commission on November 3, 2016, (as amended, the “Schedule 13D”), and is filed by the Reporting Persons with respect to the common stock, par value $0.01 per share (the “Common Stock”), of Albireo
Pharma, Inc. (the “Issuer”). Capitalized terms used herein but not defined
| Item 5. |
Interest in Securities of the Issuer.
|
(a)-(b):
Number of shares of Common Stock beneficially owned:
|
Phase4 Partners
|
0 shares
|
|
Phase4 III
|
0 shares
|
|
Phase4 GPLP
|
0 shares
|
|
Phase4 GP
|
0 shares
|
|
Dr. Alastair McKinnon
|
0 shares
|
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
|
Charles Sermon
|
0 shares
|
Percent of class:
|
Phase4 Partners Limited
|
0%
|
|
Phase4 Ventures III LP
|
0%
|
|
Phase4 Ventures III GP LP
|
0%
|
|
Phase4 Ventures III General Partner Limited
|
0%
|
|
Dr. Alastair McKinnon
|
0%
|
|
Dr. Denise Scots-Knight
|
0%
|
|
Charles Sermon
|
0%
|
The percentage ownership was calculated based on 11,897,146 shares of common stock outstanding as of the March 1, 2018, as disclosed in the Annual Report on
Form 10-K for the fiscal year ended December 31, 2018 filed by Albireo Pharma, Inc. (the “Issuer”) with the Securities and Exchange Commission on March 27, 2018.
Number of shares as to which such person has:
| (i) |
Sole power to vote or to direct the vote:
|
|
Phase4 Partners
|
0 shares
|
|
Phase4 III
|
0 shares
|
|
Phase4 GPLP
|
0 shares
|
|
Phase4 GP
|
0 shares
|
|
Dr. Alastair McKinnon
|
0 shares
|
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
|
Charles Sermon
|
0 shares
|
| (ii) |
Shared power to vote or to direct the vote:
|
|
Phase4 Partners
|
0 shares
|
|
Phase4 III
|
0 shares
|
|
Phase4 GPLP
|
0 shares
|
|
Phase4 GP
|
0 shares
|
|
|
0 shares
|
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
|
Charles Sermon
|
0 shares
|
| (iii) |
Sole power to dispose or to direct the disposition of:
|
|
Phase4 Partners
|
0 shares
|
|
Phase4 III
|
0 shares
|
|
Phase4 GPLP
|
0 shares
|
|
Phase4 GP
|
0 shares
|
|
Dr. Alastair McKinnon
|
0 shares
|
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
|
Charles Sermon
|
0 shares
|
| (iv) |
Shared power to dispose or to direct the disposition of:
|
|
Phase4 Partners
|
0 shares
|
|
Phase4 III
|
0 shares
|
|
Phase4 GPLP
|
0 shares
|
|
Phase4 GP
|
0 shares
|
|
Dr. Alastair McKinnon
|
0 shares
|
|
Denise Scots-Knight, Ph.D.
|
0 shares
|
|
Charles Sermon
|
0 shares
|
Between January 31, 2018 and May 11, 2018, the Reporting Persons sold 479,894 shares of Common Stock in the aggregate for $15,864,253.89.
|
Date
|
Number of Shares of
Common Stock
|
Price per Share*
|
Price Range
|
|
|
01/31/18
|
1,200
|
35.1000
|
$35.00
|
$35.18
|
|
02/01/18
|
2,802
|
35.1790
|
$35.00
|
$35.68
|
|
02/02/18
|
1,504
|
35.0057
|
$35.00
|
$35.10
|
|
02/05/18
|
4,397
|
35.2435
|
$35.00
|
$35.97
|
|
02/05/18
|
100
|
36.2400
|
$36.24
|
$36.24
|
|
02/06/18
|
947
|
35.0000
|
$35.00
|
$35.00
|
|
02/07/18
|
10,900
|
35.1653
|
$34.50
|
$35.50
|
|
02/07/18
|
3,800
|
35.7621
|
$35.51
|
$36.00
|
|
02/08/18
|
3,265
|
34.9687
|
$34.50
|
$35.46
|
|
02/08/18
|
6,735
|
36.1012
|
$35.88
|
$36.25
|
|
02/09/18
|
2,366
|
34.5767
|
$34.50
|
$34.66
|
|
02/12/18
|
3,954
|
35.1117
|
$34.55
|
$35.55
|
|
02/12/18
|
16,046
|
36.1772
|
$35.81
|
$36.76
|
|
02/13/18
|
5,068
|
35.2218
|
$34.73
|
$35.73
|
|
02/13/18
|
4,932
|
36.0705
|
$35.74
|
$36.36
|
|
02/14/18
|
9,900
|
35.6986
|
$35.02
|
$36.00
|
|
02/14/18
|
100
|
36.1500
|
$36.15
|
$36.15
|
|
02/15/18
|
9,700
|
35.6332
|
$35.16
|
$36.18
|
|
02/15/18
|
300
|
36.1767
|
$36.17
|
$36.18
|
|
02/16/18
|
5,984
|
34.8840
|
$34.50
|
$35.44
|
|
02/20/18
|
5,617
|
34.7734
|
$34.50
|
$35.21
|
|
02/21/18
|
1,260
|
34.5998
|
$34.50
|
$34.87
|
|
02/26/18
|
4,121
|
34.7987
|
$34.50
|
$35.02
|
|
02/27/18
|
92
|
34.5000
|
$34.50
|
$34.50
|
|
02/28/18
|
200
|
34.5200
|
$34.50
|
$34.54
|
|
03/02/18
|
12,405
|
34.8597
|
$34.50
|
$35.44
|
|
03/05/18
|
5,053
|
34.7777
|
$34.50
|
$35.27
|
|
03/06/18
|
2,936
|
34.6519
|
$34.50
|
$34.89
|
|
03/07/18
|
10,769
|
34.9047
|
$34.50
|
$35.33
|
|
03/08/18
|
400
|
34.6850
|
$34.50
|
$34.81
|
|
03/09/18
|
47
|
34.5000
|
$34.50
|
$34.50
|
|
03/12/18
|
6,761
|
34.5595
|
$34.50
|
$34.89
|
|
03/13/18
|
12,255
|
35.0308
|
$34.52
|
$35.49
|
|
03/13/18
|
7,745
|
35.9139
|
$35.54
|
$35.49
|
|
03/14/18
|
9,189
|
35.3852
|
$34.78
|
$35.77
|
|
03/14/18
|
2600
|
36.0258
|
$35.79
|
$36.14
|
|
03/15/18
|
20,000
|
35.4025
|
$34.96
|
$35.95
|
|
03/16/18
|
15,400
|
35.4134
|
$34.70
|
$35.70
|
|
03/16/18
|
4,600
|
35.9843
|
$35.73
|
$36.25
|
|
03/19/18
|
29,059
|
36.3784
|
$35.86
|
$36.86
|
|
03/19/18
|
466
|
37.0880
|
$36.90
|
$37.60
|
|
03/19/18
|
500
|
38.056
|
$37.92
|
$38.46
|
|
03/20/18
|
4,700
|
35.1972
|
$34.84
|
$35.62
|
|
03/20/18
|
13,636
|
36.1751
|
$35.92
|
$36.50
|
|
03/21/18
|
3,490
|
34.6079
|
$34.50
|
$35.09
|
|
03/22/18
|
500
|
< div style="text-align: center">34.5320 |
$34.50
|
$34.60
|
|
04/12/18
|
3,905
|
34.5003
|
$34.50
|
$34.76
|
|
04/20/18
|
2,700
|
34.5000
|
$34.50
|
$34.50
|
|
04/23/18
|
3,614
|
32.6157
|
$32.22
|
$32.98
|
|
04/24/18
|
2,534
|
32.2880
|
$32.00
|
$33.00
|
|
05/04/18
|
24,384
|
29.1079
|
$29.00
|
$29.40
|
|
05/04/18
|
8,901
|
29.6576
|
$29.41
|
$30.41
|
|
05/07/18
|
21,161
|
29.0413
|
$29.00
|
$29.33
|
|
05/08/18
|
45,554
|
29.0780
|
$29.00
|
$29.30
|
|
05/09/18
|
50,000
|
30.0009
|
$30.00
|
$30.24
|
|
05/10/18
|
4,872
|
31.0206
|
$31.00
|
$31.25
|
|
05/11/18
|
44,468
|
31.0014
|
$31.00
|
$31.24
|
(c) Between February 5, 2019 and February 27, 2019, the Reporting Persons sold 96,321 shares of Common Stock in open market transactions as follows:
|
Date
|
Number of Shares of
Common Stock
|
Price per Share*
|
Price Range
|
|
|
02/05/19
|
10,000
|
26.3426
|
$26.10
|
$26.74
|
|
02/06/19
|
10,000
|
26.0652
|
$26.00
|
$26.50
|
|
02/13/19
|
8,583
|
26.0412
|
$26.00
|
$26.10
|
|
02/14/19
|
800
|
26.0000
|
$26.00
|
$26.00
|
|
02/15/19
|
10,000
|
26.0464
|
$26.00
|
$26.34
|
|
02/19/19
|
10,000
|
26.0319
|
$26.00
|
$26.27
|
|
02/20/19
|
7,647
|
26.0000
|
$26.00
|
$26.00
|
|
02/22/19
|
10,000
|
26.0174
|
$26.00
|
$26.35
|
|
02/25/19
|
10,000
|
26.0943
|
$26.00
|
$26.50
|
|
02/26/19
|
10,000
|
25.9642
|
$25.85
|
$26.51
|
|
02/26/19
|
2,669
|
27.4354
|
$27.30
|
$27.75
|
|
02/27/19
|
422
|
26.9170
|
$26.29
|
$27.21
|
|
02/27/19
|
6200
|
27.4158
|
$27.33
|
$27.53
|
*The number of securities reported represent an aggregate number of shares executed by a broker-dealer in multiple market transactions over a
range of prices. The price per share reported represents the weighted-average price (without regard to brokerage commissions and fees). The Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request,
the number of shares executed at each separate price within the range.
Except as set forth above, the Reporting Persons have not effected any transactions with respect to the shares of the Common Stock during the past
60 days.
(d) Not applicable.
(e) As of May 11, 2018, the reporting persons ceased to be the beneficial owners of more than five percent of the class of Common Stock of the
Issuer.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and
correct.
|
Date: March 13, 2019
|
PHASE4 PARTNERS LIMITED
|
|
|
By:
|
/s/ Charles Sermon | |
|
Name: Charles Sermon
|
||
|
Title: Director
|
||
|
Date: March 13, 2019
|
PHASE4 VENTURES III LP
|
|
|
By: Phase4 Partners Limited, its Manager
|
||
|
By:
|
/s/ Charles Sermon | |
|
Name: Charles Sermon
|
||
|
Title Director
|
||
|
Date: March 13, 2019
|
PHASE4 VENTURES III GP LP
|
|
|
By: Phase4 Ventures III General Partner Limited,
|
||
|
its general partner
|
||
|
By:
|
/s/ Charles Sermon | |
|
Name: Charles Sermon
|
||
|
Title Director
|
||
|
Date: March 13, 2019
|
PHASE4 VENTURES III GENERAL PARTNER
|
|
|
LIMITED
|
||
|
By:
|
/s/ Charles Sermon | |
|
Name: Charles Sermon
|
||
|
Title Director
|
||
|
Date: March 13, 2019
|
/s/ Alastair McKinnon | |
|
Alastair McKinnon
|
||
|
Date: March 13, 2019
|
/s/ Denise Scots-Knight | |
|
Denise Scots-Knight
|
||
|
Date: March 13, 2019
|
/s/ Charles Sermon | |
|
Charles Sermon
|
||